Prakash Thanikachalam

Prakash Thanikachalam

Auto-generated profile, based on publicly available information

Prakash Thanikachalam

Department of Urology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston PR2 9HT, UK

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2025 in Radiation
Verified
Journal Article
Open access
PDF file
LELeonie Eastlake
Leonie Eastlake
PTPrakash Thanikachalam
Prakash Thanikachalam
DCDavid Richard Cameron
David Richard Cameron
DDDimitri Dimitroyannis
Dimitri Dimitroyannis
WIWanda Ingham
Wanda Ingham
DHDennis Hadjiyiannakis
Dennis Hadjiyiannakis
Low-dose radiotherapy had historically been used to treat both bacterial and viral pneumonias. In the present day, this is not in use due to the development of antibiotics and other supportive measures as well as a concern regarding late radiation toxicities. COVID-19 presented us with a novel respiratory illness without a strong evidence-based best practice; it was thought, therefore, that there may be a role for low-dose radiotherapy in the absence or failure of a standard treatment. The rationale for this was based around the ability of low-dose radiation to reduce an inflammatory state. We treated two individuals suffering from severe COVID-19 with low-dose whole lung radiotherapy, in the setting of a phase I trial. Both patients improved clinically, biochemically, and radiologically within a matter of days. We discuss why the meta-analyses may not have shown this advantage.